Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000620164 | SCV000739982 | uncertain significance | Cardiovascular phenotype | 2022-11-21 | criteria provided, single submitter | clinical testing | The p.F23L variant (also known as c.69T>G), located in coding exon 1 of the ACTC1 gene, results from a T to G substitution at nucleotide position 69. The phenylalanine at codon 23 is replaced by leucine, an amino acid with highly similar properties. A different alteration located at the same position, resulting in the same protein change, c.67T>C p.F23L, was observed in two individuals reported to have hypertrophic cardiomyopathy; however, clinical details were limited (Coppini R et al. J Am Coll Cardiol. 2014;64:2589-600). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |